Cargando…

Cronkhite-Canada Syndrome Associated with Metastatic Colon Cancer

Cronkhite-Canada syndrome is characterized by gastrointestinal and ectodermal manifestations. In this paper, we describe a 64-year-old Iranian male, presenting with Cronkhite-Canada syndrome with metastatic colon cancer. The patient was suffering from hair loss, which occurred on the scalp at first...

Descripción completa

Detalles Bibliográficos
Autores principales: Haghighi, Shirin, Noorali, Sima, Mohammad Alizadeh, Amir Houshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968282/
https://www.ncbi.nlm.nih.gov/pubmed/29805353
http://dx.doi.org/10.1159/000479220
_version_ 1783325739504893952
author Haghighi, Shirin
Noorali, Sima
Mohammad Alizadeh, Amir Houshang
author_facet Haghighi, Shirin
Noorali, Sima
Mohammad Alizadeh, Amir Houshang
author_sort Haghighi, Shirin
collection PubMed
description Cronkhite-Canada syndrome is characterized by gastrointestinal and ectodermal manifestations. In this paper, we describe a 64-year-old Iranian male, presenting with Cronkhite-Canada syndrome with metastatic colon cancer. The patient was suffering from hair loss, which occurred on the scalp at first and then, during 5 months, extended to the whole body. After that, his sense of taste was impaired, and 2 months later, gastrointestinal symptoms gradually started, with weight loss of 20 kg over 2 months with an initial weight of 100 kg. Finally, he was admitted to our center 10 months after the onset of symptoms. On skin examination, generalized hair loss and hyperpigmentation and dysmorphic nail changes were observed. Multiple polyps within the colon and sigmoid were observed on colonoscopy. According to biopsies, a serrated adenoma and an invasive adenocarcinoma were reported in the ascending colon and sigmoid, respectively. Other polyps were pseudopolyps, and their characteristics were not significant. Computed tomography of the lungs and abdomen showed multiple adenopathies. On biopsy, metastatic adenocarcinoma was reported. The patient underwent chemotherapy with FOLFIRI and ERBITUX. Finally, after 5 courses of chemotherapy, his regimen was changed to FOLFOX and Avastin because of evidence of progression on computed tomography. The etiology of Cronkhite-Canada syndrome is currently unknown, and the optimal therapy has not been reported so far. This syndrome has many complications; the major of them is malignancy, and the prognosis is poor with a mortality rate of 50%. Therefore, annual monitoring is necessary in these patients.
format Online
Article
Text
id pubmed-5968282
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-59682822018-05-25 Cronkhite-Canada Syndrome Associated with Metastatic Colon Cancer Haghighi, Shirin Noorali, Sima Mohammad Alizadeh, Amir Houshang Case Rep Gastroenterol Single Case Cronkhite-Canada syndrome is characterized by gastrointestinal and ectodermal manifestations. In this paper, we describe a 64-year-old Iranian male, presenting with Cronkhite-Canada syndrome with metastatic colon cancer. The patient was suffering from hair loss, which occurred on the scalp at first and then, during 5 months, extended to the whole body. After that, his sense of taste was impaired, and 2 months later, gastrointestinal symptoms gradually started, with weight loss of 20 kg over 2 months with an initial weight of 100 kg. Finally, he was admitted to our center 10 months after the onset of symptoms. On skin examination, generalized hair loss and hyperpigmentation and dysmorphic nail changes were observed. Multiple polyps within the colon and sigmoid were observed on colonoscopy. According to biopsies, a serrated adenoma and an invasive adenocarcinoma were reported in the ascending colon and sigmoid, respectively. Other polyps were pseudopolyps, and their characteristics were not significant. Computed tomography of the lungs and abdomen showed multiple adenopathies. On biopsy, metastatic adenocarcinoma was reported. The patient underwent chemotherapy with FOLFIRI and ERBITUX. Finally, after 5 courses of chemotherapy, his regimen was changed to FOLFOX and Avastin because of evidence of progression on computed tomography. The etiology of Cronkhite-Canada syndrome is currently unknown, and the optimal therapy has not been reported so far. This syndrome has many complications; the major of them is malignancy, and the prognosis is poor with a mortality rate of 50%. Therefore, annual monitoring is necessary in these patients. S. Karger AG 2018-04-13 /pmc/articles/PMC5968282/ /pubmed/29805353 http://dx.doi.org/10.1159/000479220 Text en Copyright © 2018 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Single Case
Haghighi, Shirin
Noorali, Sima
Mohammad Alizadeh, Amir Houshang
Cronkhite-Canada Syndrome Associated with Metastatic Colon Cancer
title Cronkhite-Canada Syndrome Associated with Metastatic Colon Cancer
title_full Cronkhite-Canada Syndrome Associated with Metastatic Colon Cancer
title_fullStr Cronkhite-Canada Syndrome Associated with Metastatic Colon Cancer
title_full_unstemmed Cronkhite-Canada Syndrome Associated with Metastatic Colon Cancer
title_short Cronkhite-Canada Syndrome Associated with Metastatic Colon Cancer
title_sort cronkhite-canada syndrome associated with metastatic colon cancer
topic Single Case
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968282/
https://www.ncbi.nlm.nih.gov/pubmed/29805353
http://dx.doi.org/10.1159/000479220
work_keys_str_mv AT haghighishirin cronkhitecanadasyndromeassociatedwithmetastaticcoloncancer
AT nooralisima cronkhitecanadasyndromeassociatedwithmetastaticcoloncancer
AT mohammadalizadehamirhoushang cronkhitecanadasyndromeassociatedwithmetastaticcoloncancer